Anixa Biosciences closed at $3.28 on Nov 4, up 7.37%, 37.2% below its 52-week closing high. Volume of 220.1K shares was 1.14× its 20-day average (close to normal).
Split-adjusted performance: +8.6% over one month, +7.2% over six months, -20.8% over one year.
Short interest was 1.7M shares at the Oct 15 settlement, up 23.1% from the prior report (7.4% of float, 6.4 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| ANIXAnixa Biosciences | $3.28 | +7.37% | +7.2% | — | — | — | $114.0M | |
| ORGOOrganogenesis Holdings | $0.8700 | +4.19% | −66.0% | −56.7% | −227.0% | — | $111.9M | Compare |
| EQEquillium | $1.40 | −0.71% | −35.5% | — | — | — | $109.7M | Compare |
| HURATuHURA Biosciences | $1.72 | +3.93% | −32.3% | — | — | — | $109.6M | Compare |
| IMUXImmunic | $7.94 | +4.47% | −27.9% | — | — | — | $108.3M | Compare |
| NRXPNRX Pharmaceuticals | $2.49 | +11.16% | −18.4% | — | −1500.5% | — | $107.8M | Compare |
| NERVMinerva Neurosciences | $2.57 | +9.36% | −58.7% | — | — | — | $122.7M | Compare |
| NKTXNkarta | $1.73 | +13.07% | −47.9% | — | — | — | $123.9M | Compare |
| OKUROnKure Therapeutics | $2.59 | +3.60% | −36.4% | — | — | — | $104.9M | Compare |
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
